Nanochap

Initially targeting the consumer electronics market with signal conditioning ASICs for products like accelerometers and pressure sensors, the leadership team made a strategic pivot in 2015. Recognizing the limited market size of their initial niche, they redirected the company's focus toward the more demanding and higher-barrier industrial and automotive sectors. This strategic shift involved expanding into isolation chips, a critical component for high-end industrial applications. The company has since secured significant funding, including a Series A round in 2016 and a Series B round in 2019, to fuel its growth.

Nanochap's business model is centered on designing and supplying core biochip technology to a global client base across healthcare, smart home, and beauty care industries. The company operates a comprehensive industrial chain, managing wafer and MEMS packaging, and supplying both in-vitro/implantable components and finished products. Its product portfolio is extensive, featuring biochips designed for nerve stimulation and biosensing. Key offerings include high-density and programmable neural stimulation chips (like NNC_Pstim320, ENS001), vital sign detection chips (EPC001), biomolecular signal processing chips (BMS002), and EEG/EMG detection modules. These components enable the monitoring of human physiological parameters for health analysis and find application in devices like advanced body fat scales and even immersive gaming for realistic somatosensory feedback. A notable project under development is a high-resolution artificial retina, positioning the company at the forefront of brain-computer interface technology.